withangulatin a has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Kong, LY; Li, Y; Lin, YL; Liu, XQ; Luo, JG; Wu, XT; Zhou, WX | 1 |
1 other study(ies) available for withangulatin a and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Glutaminase; Humans; Molecular Structure; Pregnenes; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2021 |